|

Ivosidenib combined with venetoclax and azacitidine Clinical Trials

1 actively recruiting trial

Also known as: Fit Arm, Unfit Arm

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1

Indications

  • Ivosidenib1
  • IDH1 Gene Mutation1
  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.